David Jonathan Castle
MBChB, MSc, MD, FRCPsych, FRANZCP
Qualification
- MD
- FRANZCP
- FRCPsych
Professional Memberships
- RANZCP
- RCPsych
- ICOCS
- ECNP
Dr. David Jonathan Castle (he/him) is currently Professor, Department of Psychiatry, University of Tasmania, and Consultant Psychiatrist, Royal Hobart Hospital, Tasmania, Australia. Prior to this, he was Professor of Psychiatry at St Vincent’s Health and The University of Melbourne for 15 years and spent two years as Inaugural Director of the Centre for Complex Interventions, University of Toronto, Toronto, Canada.
His clinical and research interests are broad, including schizophrenia, bipolar disorder, substance abuse, obsessive-compulsive disorder, and OC spectrum disorders (notably body dysmorphic disorder). He has extensive experience in clinical trials, including those in mood disorders. He has been successful in attracting substantial grant funding from a variety of sources and has strong local, national, and international research links.
He has received a number of commendations for his work, including the Senior Research Award from the Royal ANZ College of Psychiatrists (RANZCP) and a University of Melbourne Vice-Chancellor’s Staff Engagement Award. In 2015, he was presented with the Ian Simpson Award by the RANZCP in recognition of outstanding contributions to clinical psychiatry as assessed through service to patients and the community. He has published widely in prestigious journals, produced 28 books, and delivered scientific talks around the world. He is passionate about teaching and mentoring junior colleagues.
Grants
2022-26 *Principal Applicant: Lewis GF. Mental health leads: Selby P, Sherifali D, Castle D. “Mobilizing Knowledge and Implementing Equitable and Cost-Effective Health and Social Care Services for Persons Living with Diabetes in Canada” Diabetes Action Canada (DAC) SPOR Network – Knowledge Mobilization and Implementation Science. CIHR: CAD$3,750,000
2022-26 Thomas N, Rossell S, Bell I, Brand R, Thompson A, Castle D, Meyer D, Longden E, Wadley G, Pulik-White G, Birkedal Glenthoej L, Banbury A, Hillard B, Seabrook L “Avatar-mediated therapy for hallucinations: superiority trial (AMETHYST)” NHMRC AUD$1,764,774 (2015133)
2022-24 *Principal Applicant: Hawke LD; Co-Applicants: Stergiopoulos V, Campbell B, van Kesteren MR, Cappe V, Dawthorne M, Stewart D, Rajji T, Simpson S, Castle D, Chandler J, Shields R, Paterson J, Buchman D, Gupta M. “Suicide and medical assistance in dying for mental illness: A qualitative study” University of Toronto Department of Psychiatry and CAMH: CAD$50,000
2022-25 *Principal Applicant: Husain MI. Co-Investigators: Blumberger D, Castle D, Kloiber S, Mulsant B, Ortiz A, Rosenblat J, Wang W. “A proof-of-concept randomised controlled trial to show that the antidepressant effects of psilocybin do not require psychedelic effects” CIHR Project Grant: CAD$546,976
2022-27 Choong P, Clark J, Mukherjee P, Di Bella C, Moulton SE, Duchi S, O’Connell CD, Beirne ST, Gambhir S, Chung J, Gupta R, Dowsey MM, Spelman TD, Castle DJ, Shields N, Tanner C, Gardner J, Bunzil S, Clarke PM, Schilling C, Sagnella S, Ronchi AJ, Rushbrooke E, Dusseldorp JR. “Cartilage based stem cell therapies for joint deformity and facial disfigurement. A framework for point-of-care manufacturing and delivery (ARISTOCRAT)” MRFF Stem Cell Therapies Mission AUD$7,000,000 (2017213)
2022-2023 Ski CF, Shenton M, Thompson DR, Castle DJ. “Long COVID Optimal Health Programme” Norfolk and Suffolk Primary and Community Care Research Office Research Capability Funding £9,353
2022-2025 *Principal Applicant: Hsiang-Yuan L; Co-apps: Ameis SH, Castle D, Desarkar P, Diaconescu A, Hawco C, Husain I, Lai M-C, Lunsky Y, Rajji T, Wang W. “Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial with Pre-Post Brain and Cognitive Measurement to Understand Mechanisms” Labatt Family Innovation Fund in Brain Health CAD$340,000
2023-2025 *Principal Applicant: Castle D. “An online/in-person program utilizing Acceptance Commitment Therapy (ACT)-Matrix plus contingency management (CM) for methamphetamine use disorder (MUD)” Health Canada CAD$841,212
2023-2025 *Principal Applicant: Le Foll B; Co-applicants: Castle D, Chen J, Hassan A, Husain I, Ma C, Sloan MLai M-C, Lunsky Y, Rajji T, Wang W. “Pilot clinical trial: Psilocybin assisted psychotherapy as a novel treatment for comorbid Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD)” Canadian Institutes of Health Research CAD$344,250
2023-2024 *Principal Applicants: Stergiopoulos V, Kurdyak PA, Canning C, Lo BF. Co-Investigators: Agarwal S, Burhan A, Castle D, Del Giudice L, Konkoly-Thege B, Melamed O, Sirotich F, Sockalingam S, Strudwick G, Tarijian T, Tibbo P, Vigo D. “Strengthening the delivery of integrated care in specialised mental health settings for adults experiencing serious mental illness” CIHR Catalyst Grant: CAD$148,733 (492123)
2023-2024 Rossell S, Finkelstein C, Phillipou A, Castle D, Soha O, Roy A. “Psilocybin for treatment of body image disturbances in anorexia nervosa: an embodied solution to an embodied problem” Barbara Dicker Brain Sciences Foundation AU$20,000
2023-2024 Haines T, et al. (Heinsch M, Castle D Tasmanian site leads) National Mental Health Pathways to Practice Program - GO6018 AUD$4,800,000
2023-2024 Nevarez-Flores A, Neil A, Castle D, Kilpatrick M, Mendoza Diaz A, Foa L, McDermott B. “Tasmanian Suicide Prevention Strategy 2023-2027 Evaluation Framework” Tasmanian Health Service AUD$500,000
2023-2028 Curtis J, Castle D, et al. “No-one left behind: Integrated Physical Healthcare for people living with a serious mental illness” NHMRC TCR Improving Physical Health of People with a Mental Illness (2025162): AUD$2,996,738
2024 Hopwood M, Castle D. Evidence-based guidelines for weight management in people with a mental illness” iNova (investigator initiated grant): AUD$16,500
2024 Peak J, Neil A, Mendoza Diaz A, Kilpatrick M, Foa L, McDermott B, Castle D. “Evaluation of the Tasmanian PACER service” Tasmanian Health Service AUD$62,052
2024 Nevarez-Flores A, Neil A, Mendoza Diaz A, Kilpatrick M, Foa L, McDermott B, Castle D. “Means restriction and suicidality by firearm” Tasmanian Health Service AUD$55,511
2024 Neil A, Castle D, et al. “Are literacy skills recorded during history taking in mental health services? An objective assessment of practice” Royal Hobart Hospital Foundation AUD$24,988
2024-2025 Mendoza Diaz A, Castle D, McDermott B, Foa L, Kilpatrick M, Nevarez-Flores A, Neil A, Pryor A, Knowles B. “A review of therapeutic care farms” Tasmanian Health Service AUD$54,000
2024-2025 Castle D. “Integrated peer support physical health service” Tasmanian Health Service AUD$99,982
2024-2025 Castle D. “Acceptance Commitment Therapy for crystal methamphetamine use disorder” Tasmanian Health Service AUD$99,224
2024-2029 Sumner P, Rossell S, Castle D, Iyer R, Haywood D, Carruthers S, Mendoza-Diaz A. “Using speech analyses for detecting suicide risk and relapse in eating disorders” NHMRC MRFF Childhood Mental Health Research (2036110): AUD$996,2942024-2025 Kilpatrick M, Perez A, Castle D. “Mapping and enhancing critical incident response and postvention practices across priority settings in Tasmania” Tasmanian Health Service AUD$97,611
2024-2025 Kilpatrick M, Perez A, Castle D. “Consultation data analysis: Development of a 20-year Preventive Health Strategy” Tasmanian Health Service AUD$32,035
2024-2025 Moore M, Castle D. “Establish a baseline assessment of patterns of self-harm and suicidal ideation presentations and admissions across Tasmanian public hospitals” Tasmanian Health Service AUD$50,000
2025-2026 McNamara K (Castle D one of a number of Co-investigators) “Translating mental health peer support into practice for consumers in rural and regional emergency departments: feasibility and pilot testing” Medibank Foundation AUD$80,000
Recent Publications
773. *Acevedo N, Castle D, Bosanac P, Rossell S. "Clinical outcomes of deep brain stimulation for obsessive-compulsive disorder: insight as a predictor of symptom changes" Psychiatry and Clinical Neurosciences 2024; 78: 131-141
774. *Osz F, Murubi C, Kilpatrick M, Castle D. "Gonadal hormones in borderline personality disorder: implications for understanding symptoms and supporting treatment" Archives of Women's Mental Health 2023: 1-6
775. *Giles S, Hughes EK, Castle DJ, Jenkins Z, Phillipou A, Rossell S, Urbini G, Fuller-Tyszkiewicz M, Krug I. "A new network analysis model in anorexia nervosa patients based on self-reported eating disorder symptoms, psychological distress, and cognitive flexibility" British Journal of Clinical Psychology 2024; 63: 118-134
776. Li M, Jenkins Z, Rossell S, Castle D. “Assessment” In: Greenberg JL, Weingarden H (eds.) Optimizing Evidence-Based Treatment for Body Dysmorphic Disorder Springer 2024: 35-54
777. Rossell S, Castle D. “Diagnosis and clinical features” In: Greenberg JL, Weingarden H (eds.) Optimizing Evidence-Based Treatment for Body Dysmorphic Disorder Springer 2024: 1-16
778. *Sankaranarayanan A, Ramanathan P, Wilding H, Mathew R, Castle DJ. "Disordered gambling among people with psychotic disorders: A systematic review" Schizophrenia 2024; 10: 4
779. *Meyer GM, Hollunder B, Li N, Butenko K, Dembek TA, Hart L, Nombela C, Mosley P, Akram H, Acevedo N, Borron BM, Chou T, Castaño Montoya JP, Strange B, Barcia JA, Tyagi H, Castle DJ, Smith AH, Choi KS, Kopell BH, Mayberg HS, Sheth SA, Goodman W, Leentjens AFG, Richardson RM, Rossell SL, Bosanac P, Cosgrove GR, Kuhn J, Visser-Vandewalle V, Figee M, Dougherty DD, Siddiqi SH, Zrinzo L, Joyce E, Baldermann JC, Fox MD, Neudorfer C, Horn A. "Deep Brain Stimulation for Obsessive-Compulsive Disorder: Optimal stimulation sites" Biological Psychiatry 2024; 96: 101-113
780. *Acevedo N, Castle D, Rossell S. “The promise and challenges of transcranial magnetic stimulation and deep brain stimulation as therapeutic options for obsessive-compulsive disorder”
Expert Review of Neurotherapeutics 2024: doi.org/10.1080/14737175.2024.230687
|
773. *Acevedo N, Castle D, Bosanac P, Rossell S. "Clinical outcomes of deep brain stimulation for obsessive-compulsive disorder: insight as a predictor of symptom changes" Psychiatry and Clinical Neurosciences 2024; 78: 131-141 774. *Osz F, Murubi C, Kilpatrick M, Castle D. "Gonadal hormones in borderline personality disorder: implications for understanding symptoms and supporting treatment" Archives of Women's Mental Health 2023: 1-6 775. *Giles S, Hughes EK, Castle DJ, Jenkins Z, Phillipou A, Rossell S, Urbini G, Fuller-Tyszkiewicz M, Krug I. "A new network analysis model in anorexia nervosa patients based on self-reported eating disorder symptoms, psychological distress, and cognitive flexibility" British Journal of Clinical Psychology 2024; 63: 118-134 776. Li M, Jenkins Z, Rossell S, Castle D. “Assessment” In: Greenberg JL, Weingarden H (eds.) Optimizing Evidence-Based Treatment for Body Dysmorphic Disorder Springer 2024: 35-54 777. Rossell S, Castle D. “Diagnosis and clinical features” In: Greenberg JL, Weingarden H (eds.) Optimizing Evidence-Based Treatment for Body Dysmorphic Disorder Springer 2024: 1-16 778. *Sankaranarayanan A, Ramanathan P, Wilding H, Mathew R, Castle DJ. "Disordered gambling among people with psychotic disorders: A systematic review" Schizophrenia 2024; 10: 4 779. *Meyer GM, Hollunder B, Li N, Butenko K, Dembek TA, Hart L, Nombela C, Mosley P, Akram H, Acevedo N, Borron BM, Chou T, Castaño Montoya JP, Strange B, Barcia JA, Tyagi H, Castle DJ, Smith AH, Choi KS, Kopell BH, Mayberg HS, Sheth SA, Goodman W, Leentjens AFG, Richardson RM, Rossell SL, Bosanac P, Cosgrove GR, Kuhn J, Visser-Vandewalle V, Figee M, Dougherty DD, Siddiqi SH, Zrinzo L, Joyce E, Baldermann JC, Fox MD, Neudorfer C, Horn A. "Deep Brain Stimulation for Obsessive-Compulsive Disorder: Optimal stimulation sites" Biological Psychiatry 2024; 96: 101-113 780. *Acevedo N, Castle D, Rossell S. “The promise and challenges of transcranial magnetic stimulation and deep brain stimulation as therapeutic options for obsessive-compulsive disorder” Expert Review of Neurotherapeutics 2024: doi.org/10.1080/14737175.2024.2306875 781. *Stergiopoulos V, Bastidas-Bilbao H, Gupta M, Buchman DZ, Stewart DE, Rajji T, Simpson AIF, van Kestern MR, Cappe V, Castle D, Shields R, Hawke LD. “Care considerations in Medical Assistance in Dying for persons with mental illness as the sole underlying medical condition: patient and family perspectives” BMC Psychiatry 2024; 24: 120 782. *Sayrafizadeh N, Ledwos N, Husain I, Castle D. "Aggressive Behaviours Associated with MDMA and Psychedelics: A narrative review" Acta Neuropsychiatrica 2025; 37: 1-13 783. *Bastidas-Bilbao H, Castle D, Gupta M, Stergiopoulos V, Hawke LD. “Medical assistance in dying for mental illness: a complex intervention requiring a correspondingly complex evaluation approach?” British Journal of Psychiatry 2024; 225: 264-267 784. *Pikoos T, Malcolm A, Castle D, Rossell S. “A hierarchy of visual processing deficits in body dysmorphic disorder: a conceptual review and empirical investigation” Cognitive Neuropsychiatry 2024:10.1080/13546805.2024.2326243 785. *Scamvougeras A, Castle D. “Functional Neurological Disorders: Challenging the mainstream agnostic causative position” The Canadian Journal of Psychiatry 2024; 7: 07067437241245957 786. *Sanzone EM, Kam O, Sanzone KE, Bai M; Rodecker N, Shad MU, Varghese SP, Barlati S, Kirschner M, Kooner P, Velligan DI, Waszkiewicz N, Castle DJ, Cowan RL, Koola MM. “Mobile Delivery Program to prevent relapse and improve functioning in patients with psychiatric diseases" Journal of Psychiatric Practice 2024; 30: 364-373 787. *Tardelli VS, Johnstone S, Zangh M, Castle DJ. “Demographic risk factors for past year use of illegal substances in young adults and older adults” Canadian Journal of Addiction 2024; 15: 5-18 788. *Dang AB, Kiropoulos L, Castle D, Jenkins Z, Phillipou A, Rossell S, Krug I “Psychiatric comorbidity and severity in Anorexia Nervosa: A comparative study of the DSM-5, the ICD-11, and Overvaluation of Weight/Shape Severity Ratings” Eating Disorders: The Journal of Treatment & Prevention 2024; 32: 546-562 789. *Stettaford T, Fehily C, Campbell E, Barker D, Oldmeadow C, McKeon E, Love S, Lawn S, Castle D, Bowman J. “Risk prevalence, readiness and confidence to change lifestyle risk factors among clients of community mental health services” Australian and New Zealand Journal of Psychiatry 2024; 58: 702-712 790 *Raspovic A, Duck R, Synnot A, Caldwell B, Phillipou A, Castle D, Newton R, Jenkins Z, Cunich M, Maguire S, Miskovic-Wheatley J. “A Peer Mentoring Program for eating disorders: improved symptomatology and reduced hospital admissions, three years and a pandemic on” Journal of Eating Disorders 2024; 12: 99 791 *Nevarez-Flores AG, Martin A, Bartkowiak-Theron I, Makin J, Norris K, Castle D, Neil AL. “The impact of suicide registers and other monitoring systems on suicide prevention: A scoping review” International Journal of Social Psychiatry 2024; 70: 1211-1233 792 *Siddiqui S, Mehta D, Coles A, Selby P, Solmi M, Castle D. “Psychosocial interventions for individuals with comorbid psychosis and substance use disorders: Systematic review and meta-analysis of randomized studies" Schizophrenia Bulletin 2024; doi.org/10.1093/schbul/sbae101 793. *Virgili G, Neill E, Enticott P, Castle D, Rossell S. “A systematic review of visual processing deficits in body dysmorphic disorder (BDD)” Psychiatry Research 2024: 339: 16013 794. *Skiba RM, Chinchani AM, Menon M, Lepage M, Lavigne KM, Malla A, Joober R, Goldberg JO, Heinrichs W, Castle DJ, Burns A, Best MW, Rossell SL, Walther S, Woodward TS. “Overlap between individual differences in cognition and symptoms of schizophrenia” Schizophrenia Research 2024; 270: 220-228 795. *Husain MO, Hawke LD, Lu Y, Kozloff ND, Strudwick G, Kiang M, Wang W, Castle D, Foussias G. “A mixed-methods study to evaluate the feasibility and preliminary efficacy of delivering the optimal health program (OHP) for youth at clinical high risk (CHR) for psychosis: A study protocol” PLOS ONE 2024; 19: e0306968. 796. *Shadbolt C, Dowsey MM, Sharmala Thuraisingam S, Rele S, Choong P, Castle DJ, Inacio M, Schilling C. "Association between pharmacologic treatment of depression and patient-reported outcomes following total hip and knee arthroplasty" The Journal of Arthroplasty 2024; 07: 023 797. *Haywood D, Castle D, Hart N. “Avoiding the pitfalls of the DSM-5: A primer for health professionals” General Hospital Psychiatry 2024; 90: 88-90 798. *Sorkhou M, Johnstone S, Weinberger AH, Cooper ZC, Sanches M, Castle DJ, Hall W, Rabin RA, Hammond D, George TP. “Changes in cannabis use patterns in psychiatric populations pre- and post-legalization of recreational cannabis use in Canada: A repeated cross-sectional survey” Cannabis 2024; 7: 1-13 799. *Green JE, Wrobel A, Todd E, Marx W, Berk M, Lotfalian M, Castle D, Cryan JF, Athan E, Hair C, Nierenberg AA, Jacka FN, Dawson SL. “Early antibiotic exposure and risk of psychiatric and neurocognitive outcomes: A systematic review and meta-analysis” British Journal of Psychiatry 2024; doi: 10.1192/bjp.2024.121 800. Li M, Castle D. “The Dysmorphic Concern Questionnaire”. In: BDD Assessment Handbook (in press: accepted 09.08.2024) 801. *Tamrakar S, Mendoza-Diaz A, Nevarez-Florez A, Castle D. “Characterising the nature of psychiatric disorders and patterns of antipsychotic medications prescribed in a psychiatric ward in a public hospital in Tasmania” Australasian Psychiatry 2024 doi: 10.1177/10398562241283156 802. *Hawke LD, Nguyen ATP, Wang W, Brown EE, Xu D, Deuville S, Goulding S, Ski CF, Thompson DR, Rodak T, Strudwick G, Rossell SL, Castle D. “A systematic review of interventions for mental health, cognition, and psychological wellbeing in Long COVID” BMJ Mental Health 2024; 27: 1-11 803. *Zirnsak T-M, McCarter K, McKinlay ML, Guillaumier A, Cocks N, Brasier C, Hayes L, Baker AL, Baird DE, Bonevski B, Borland R, Castle D, Forbes E, Kelly PJ, Segan C, Sweeney R, Turner A, Williams JM. “Holding on to hope: Follow up qualitative findings of a tobacco treatment intervention for people experiencing mental health conditions” Frontiers 2025; doi: 10.3389 804. *Lopes JJ, Rae CD, Meyer D, Yolland C, Neill E, Castle D, Dean B, Rossell SL. “Glutamate concentrations and cognitive deficits in ultra-treatment-resistant schizophrenia: an exploratory and comparative 1H-MRS study” Psychiatry Research: Neuroimaging 2025; 347: 111926 805. *Nevarez-Flores AG, Pandey V, Perez Angelucci A, Neil AL, McDermott B, Castle D. “Means restriction for suicide prevention: an umbrella review” Acta Psychiatrica Scandinavica 2025; doi.org/10.1111/acps.13783 806. *Ambreen M, Canning C, Lo B, Agarwal SM, Burhan AM, Castle D, Del Giudice ME, Konkolÿ-Thege B, Liu L, Melamed OC, Sirotich F, Stergiopoulos V. “Strengthening the delivery of integrated care for individuals experiencing serious mental illness within mental health settings: A qualitative description of health provider perspectives” BMC Psychiatry 2025;14: 129 807. *Ambreen M, Canning C, Lo B, Agarwal SM, Burhan AM, Castle D, Del Giudice ME, Konkolÿ-Thege B, Liu L, Melamed OC, Sirotich F, Stergiopoulos V. "Strengthening the delivery of physical health care for adults living with serious mental illness: A qualitative description of patient and family member perspectives" Health Expectations (in press: accepted 02.03.2025) 808. *Nguyen ATP, Ski CF, Thompson DR, Abbey SE, Kloiber S, Sheikhan NY, Selby P, Shields R, Rossell SL, Strudwick G, Castle D, Hawke LD. “Health and social service provider perspectives on challenges, approaches, and recommendations for treating long COVID: A qualitative study of Canadian provider experiences” BMC Health Services Research 2025; 25: 1-13 809. *Wagner E, ---- Castle D (one of 12 co-authors) -- Solmi M. "Risk of all-cause and cause-specific mortality, and suicide attempt in people with anxiety and stress-related disorders: a systematic review, meta-analysis and meta-regression analysis of 165 studies" World Psychiatry (in press: accepted 03.04.2025) 810. *Lu Y, Hedemann TL, Hawke LD, Ampofo Y, Goldsmith R, Kozloff ND, Strudwick G, Kiang M, Castle D, Foussias G, Husain MO. “Adaptation of a psychosocial programme for Canadian youth at clinical high risk (CHR) for psychosis” Canadian Journal of Psychiatry 2025; 19: e0306968 811. *Constantinidis D, Hebbard G, O’Brien C, Kanaan R, Castle D. “Healthcare Transition and Inflammatory Bowel Disease: The Challenges experienced by Young Adults after Transfer from Paediatric to Adult Health Services” Psychology, Health and Medicine 2025; 2497001
Honours and Awards
|